Journal of International Reproductive Health/Family Planning ›› 2021, Vol. 40 ›› Issue (4): 314-318.doi: 10.12280/gjszjk.20210037

• Review • Previous Articles     Next Articles

Pathogenic Factors and Management Strategies of Treatment-Resistant Thin Endometrium

WANG Li-yan, FU Xiao-qian, LI Hua, YANG Yi-hua()   

  1. Guangxi Reproductive Medicine Research Center, The First Affiliated Hospital of Guangxi Medical University, Nanning 530000, China (WANG Li-yan, FU Xiao-qian, LI Hua, YANG Yi -hua);Yulin Maternity and Child Healthcare Hospital, Yulin 537000, Guangxi Zhuang Autonomous Region, China (WANG Li-yan)
  • Received:2021-01-20 Published:2021-07-15 Online:2021-07-27
  • Contact: YANG Yi-hua E-mail:workyyh@163.com

Abstract:

Endometrial receptivity is one of the main factors affecting embryo implantation rate, and endometrial thickness is an important index to evaluate endometrial receptivity. Patients with thin endometrium (TE) have poor clinical pregnancy outcome. The endometrium of most TE patients can reach a suitable thickness required for embryo implantation after estrogen treatment. However, some of TE patients cannot reach suitable thickness even though giving super-physiological dose of estrogen, which is called treatment-resistant thin endometrium (TTE). The pathogenesis of TTE is not clear. It is believed that the related factors of TTE are the insensitivity to estrogen receptor, abnormal expression of related factors and insufficient intimal blood supply. The main causes of TTE include infection, uterine cavity operation and insufficient blood flow. The causes of some patients with TTE are still unknown. At present, the clinical treatment of TTE mainly includes drug treatment, regenerative medicine and traditional Chinese medicine. Although there are a variety of treatment methods for TTE, the efficiency is still not satisfactory. This article reviews the epidemiology, high risk factors and treatment of TTE in order to provide reference for clinical treatment.

Key words: Endometrium, Receptor, estrogen, Vascular endothelial growth factors, Matrix metalloproteinase 11, Reproduction technique, assisted, Therapy